2025
Iambic’s AI-Designed HER2 Inhibitor IAM1363 Shows Early Anti-Tumor Activity in Heavily Pretreated Patients
Iambic Therapeutics; AI-designed drug; IAM1363; HER2 inhibitor; cancer; clinical trial; Phase 1/1b; ESMO 2025; brain-penetrant; tyrosine kinase inhibitor
Replimune Resubmits Melanoma Drug for FDA Approval After Initial Rejection
Replimune; RP1; Melanoma Treatment; FDA Approval; Resubmission
CatalYm Presents Long-Term Phase 1/2a Data for Visugromab at ESMO 2025
CatalYm; Visugromab; ESMO 2025; CPI-Refractory Tumors; GDF-15
Clarametyx Biosciences Strengthens Leadership Team to Accelerate Pipeline and Corporate Development Progress
Clarametyx Biosciences; leadership team; executive promotions; pipeline development; corporate development; Steve St. Onge; Brendan Doran; immune-enabling therapies; biofilm-driven chronic respiratory disease
Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer
Achieve Life Sciences; Erik Atkisson; Chief Legal Officer; Cytisinicline; FDA Approval
Weight-loss drug stocks drop after Trump pledges major price cuts
weight-loss drugs; ozempic; wegovy; novo nordisk; eli lilly; stock drop; drug pricing; trump administration; GLP-1
Roche’s Giredestrant Advances Oral SERD Debate at ESMO 2025
ESMO 2025; Giredestrant; Roche; Oral SERD; ER-Positive HER2-Negative Breast Cancer
Mixed Results for Roche’s Vamikibart in Phase III Uveitic Macular Edema Trials
Roche; vamikibart; uveitic macular edema; Phase III trials; MEERKAT trial; SANDCAT trial; vision improvement; central subfield thickness; clinical significance; ocular adverse events
Accuray Accelerates Transformation Efforts with Appointments of Experienced Executive Leaders
Accuray; transformation; executive appointments; Steve La Neve; CEO; Suzanne Winter; organizational change; operational transformation; med-tech; leadership transition
Transcarent Appoints Erica Palsis as Chief Legal Officer
Transcarent; Erica Palsis; Chief Legal Officer; Healthcare; AI